{"name":"Celldex Therapeutics","slug":"celldex-therapeutics","ticker":"CLDX","exchange":"NASDAQ","domain":"celldex.com","description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.","hq":"Hampton, NJ, USA","founded":0,"employees":"198","ceo":"","sector":"Autoimmune / Oncology","stockPrice":32.58,"stockChange":0.07,"stockChangePercent":0.22,"marketCap":"$2.6B","metrics":{"revenue":865000,"revenueGrowth":-97.8,"grossMargin":0,"rdSpend":0,"netIncome":-283646016,"cash":451457984,"dividendYield":0,"peRatio":-7.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CDX1307","genericName":"CDX1307","slug":"cdx1307","indication":"Other","status":"phase_1"},{"name":"CDX-011","genericName":"CDX-011","slug":"cdx-011","indication":"Other","status":"phase_2"},{"name":"CDX-585","genericName":"CDX-585","slug":"cdx-585","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CDX1307","genericName":"CDX1307","slug":"cdx1307","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CDX-011","genericName":"CDX-011","slug":"cdx-011","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CDX-585","genericName":"CDX-585","slug":"cdx-585","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"trial","source":"simplywall.st","summary":"Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - simplywall.st","headline":"Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcWNfZnlaSWxaWjlURG1sdS1SaFUxZ0NrLVhMNEtPenJYM3ZTaFE2WGc4SGFETm1UNm9xOEFOWXNEMmlwQ2FWRlc0ZnMtUUNGZG82ZEJIU0pPTmZiXzBYLWtIOURyYjNHSWtsT2Z3U093bVdYS2dtdXlRWEVCMm10VUZWQUJYVTNvQWZhdEFKcjF1TU53NTROc3pVRTlZTDE3a0M4UmtoaHVyc2x6aG44dFZ5WXM1Y2FjZUhSNkZR?oc=5","date":"2026-02-26","type":"regulatory","source":"TechStock²","summary":"Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone - TechStock²","headline":"Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNcEViUTFzV09uU0pOc21haFY5QW5iQ21OOHN0aFhPcW1RLUU4WnlXT25wVXdKMnUzTTlDSElCdWQwLVFVcWdTTmczNkRLVUhzak1qc05KMnVUNmtVdEtpMXd0Z3loSTVhZWdnc2F2MzZLdDEzRDFuRzg5eFJUb1NZaWljVQ?oc=5","date":"2026-02-26","type":"pipeline","source":"Investor's Business Daily","summary":"Celldex Therapeutics Stock Earns 88 RS Rating - Investor's Business Daily","headline":"Celldex Therapeutics Stock Earns 88 RS Rating - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdHpNZDJ4X3lQRHFVSXhRVGxCNHZNWUp6ZnJmLVpoZHBaUGlMSTJFYnlEYkk3Y3lKbllCcWhLeElrZkJtTzNra21VVEJVTHlGaU1Qb19xNzJOclhRYWVvTHZLTzdBemozTkRsUEM5d3I1TkJ4R2FreVBfSVZzVkgyay1RdVotZmw4RDhHOWRyRklMME41Yk9pVU91UWZXcUVBeDNYM242WkFxa0JNclZiRkM2UDM0eElBZFhyY0lFaDdhUmhu?oc=5","date":"2026-02-25","type":"pipeline","source":"Stocktwits","summary":"CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent - Stocktwits","headline":"CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"globenewswire.com","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - globenewswire.com","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQZnB4RzJwaHMxek83RnU3emVBYzQzTkI3SHZzbk52ZW53X2E0d0xMU1FQNHZZMXU0QmY5cXc5LXJpakxrRWRNY2ZFTmp5N2hpN1NEajF2QzhwUXpuT29vYkNmM2o2OF82dUk5bWJFVXpSeGRHd3BoUTBvd3BHajF2OGNRa1RUT2IxMW14WTh0X0t3RzQzQS1JRU1n?oc=5","date":"2025-11-14","type":"pipeline","source":"Fierce Pharma","summary":"LB Pharma, Celldex hire commercial heads as launch plans ramp up - Fierce Pharma","headline":"LB Pharma, Celldex hire commercial heads as launch plans ramp up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOcWlNVDh0bnpKUXVCRF93VWlzUkFWVzA4aWZfMW1hVkVYT0xaeDV0VVlaa3pSY1g0Wjk1azRYa0ZMaV9jLW9tTHVhWG00RGo2NjJlbjhKUzNYbURLNHZiNXFFLWt0cEVROVg0V25Rbk9FaWtyaldrVmpoU1diUzhDbzQ1eGg2Z0M5V0lvc0xfN09EOHJRWEZCZFNNdkxQYUdlSWhEMXZfSQ?oc=5","date":"2025-11-14","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ovid eyes next chapter with CEO transition - Fierce Biotech","headline":"Chutes & Ladders—Ovid eyes next chapter with CEO transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1aMXhSRm1wN3hQZkRGMjA4djd4RkhiV255SlRuLXlSMlBNb0JYbGlfd2VnWFF4OU1rcDNmZFdrZE1RSnluNlAxM29BN0lGREt6dFNz?oc=5","date":"2025-08-20","type":"pipeline","source":"FirstWord Pharma","summary":"Celldex nixes development of barzolvolimab in eosinophilic esophagitis - FirstWord Pharma","headline":"Celldex nixes development of barzolvolimab in eosinophilic esophagitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQb2ZDam5tTzgtWFZESEYtNzRKWElLSVdXN01YX0tqczJzTHNBMWVHeFV6NS1BbVdqSEhsajJvUjIxNmlPdmlWdmF3YmpiWDR0ZkJtRGxzcnpZcU5HYU9kUC1jNEtWWU9nSVB3Q1Z4T0I3T2VncEowSTlkUmpWUVFOWlRlWlk?oc=5","date":"2025-07-31","type":"pipeline","source":"Yahoo Finance","summary":"KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight - Yahoo Finance","headline":"KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBXUUdvLTBYbGwwcVBfTi1TYmdybmIyMHlnWTZSRUo2RWd3OG1BRUIzc3dER0lOUHZ3QkdyV051OXJrREhfWVk2SEFBdVpOaG1Kc243Nm9yR2JwY2hEWkZJajljMFJSZTNB?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"Celldex Therapeutics (CLDX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Celldex Therapeutics (CLDX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQTXIyV25kYldYT05pNTZmTFQ2M05PeUthLVBRcTVGclVLcjZYeVF4eGVfb1pDeXQ2SXUtbF95M2pydm9CM2szUmdpR1U0NUJ6aUlMbGI1YUdKOF9xU0h5c2x4ZkZjdXY5T2lrRm1PQ0NGa2JRMU5FUUlZUWtwTlhBU1lmdVRDcW12WDM4QU5KOUNfUm9QVElfR01DRQ?oc=5","date":"2023-11-06","type":"trial","source":"BioPharma Dive","summary":"Celldex’s reinvention advances with inflammatory disease drug data - BioPharma Dive","headline":"Celldex’s reinvention advances with inflammatory disease drug data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNOUNEZDhoeTE5Rkd0VzlfVFNhOGFtc1luZzFwMXlzR0l1V05WbzRfakxVS2tGU3F0OHlTUmdiY09KRDhPa0NNb0NNWWIzY2wxVWdYT1pQUEdWQXR1OEFMR1U5aTdLX1oyaHNiT2RjX21mODYzOVZHdHRSalpENEN3S2NFQjM3NWFtMndpMnl0Ukd4YWY5VGFmX0lUdkd3ckJDVzQ5dk9BQ0pPdFVVTXRWUlln?oc=5","date":"2023-11-06","type":"pipeline","source":"MedCity News","summary":"Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds - MedCity News","headline":"Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":1545000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1545000},{"period":"2024-12-31","value":7020000},{"period":"2023-12-31","value":6883000},{"period":"2022-12-31","value":2357000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":245074000,"rdSpendHistory":[{"period":"2025-12-31","value":245074000},{"period":"2024-12-31","value":163550000},{"period":"2023-12-31","value":118011000},{"period":"2022-12-31","value":82258000}],"sgaSpend":43838000,"operatingIncome":-287367000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-287367000},{"period":"2024-12-31","value":-195078000},{"period":"2023-12-31","value":-142042000},{"period":"2022-12-31","value":-107096000}],"netIncome":-258757000,"netIncomeHistory":[{"period":"2025-12-31","value":-258757000},{"period":"2024-12-31","value":-157863000},{"period":"2023-12-31","value":-141429000},{"period":"2022-12-31","value":-112325000}],"eps":-2.45,"epsHistory":[{"period":"2024-12-31","value":-2.45},{"period":"2023-12-31","value":-2.92},{"period":"2022-12-31","value":-2.4},{"period":"2021-12-31","value":-1.64}],"cash":28871000,"cashHistory":[{"period":"2025-12-31","value":28871000},{"period":"2024-12-31","value":28356000},{"period":"2023-12-31","value":34814000},{"period":"2022-12-31","value":29429000}],"totalAssets":582983000,"totalLiabilities":55818000,"totalDebt":2336000,"equity":527165000,"operatingCashflow":-210945000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-210945000},{"period":"2024-12-31","value":-157778000},{"period":"2023-12-31","value":-107291000},{"period":"2022-12-31","value":-103732000}],"capex":-2714000,"capexHistory":[{"period":"2025-12-31","value":-2714000},{"period":"2024-12-31","value":-1919000},{"period":"2023-12-31","value":-1818000},{"period":"2022-12-31","value":-1828000}],"freeCashflow":-213659000,"dividendsPaid":null,"buybacks":null,"employees":198,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11941000,"ebit":-87153000,"ebitda":-86337000,"period":"2025-12-31","revenue":121000,"epsBasic":-1.22,"netIncome":-81317000,"rdExpense":75333000,"epsDiluted":-1.22,"grossProfit":null,"operatingIncome":-87153000},{"sga":10686000,"ebit":-73617000,"ebitda":-72793000,"period":"2025-09-30","revenue":0,"epsBasic":-1.01,"netIncome":-67044000,"rdExpense":62931000,"epsDiluted":-1.01,"grossProfit":null,"operatingIncome":-73617000},{"sga":10391000,"ebit":-63857000,"ebitda":-62984000,"period":"2025-06-30","revenue":730000,"epsBasic":-0.85,"netIncome":-56600000,"rdExpense":54196000,"epsDiluted":-0.85,"grossProfit":null,"operatingIncome":-63857000},{"sga":10820000,"ebit":-62739000,"ebitda":-61872000,"period":"2025-03-31","revenue":695000,"epsBasic":-0.81,"netIncome":-53796000,"rdExpense":52614000,"epsDiluted":-0.81,"grossProfit":null,"operatingIncome":-62739000},{"sga":10263000,"ebit":-56027000,"ebitda":-55208000,"period":"2024-12-31","revenue":1175000,"epsBasic":-0.71,"netIncome":-47092000,"rdExpense":46939000,"epsDiluted":-0.71,"grossProfit":null,"operatingIncome":-56027000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":32.58,"previousClose":32.51,"fiftyTwoWeekHigh":35.79,"fiftyTwoWeekLow":18.55,"fiftyTwoWeekRange":"18.55 - 35.79","fiftyDayAverage":31.97,"twoHundredDayAverage":26.97,"beta":0.98,"enterpriseValue":2102227200,"forwardPE":-7.1,"priceToBook":4.75,"priceToSales":2956.38,"enterpriseToRevenue":2430.32,"enterpriseToEbitda":-6.88,"pegRatio":0,"ebitda":-305696000,"ebitdaMargin":0,"freeCashflow":-126271376,"operatingCashflow":-222160992,"totalDebt":1908000,"debtToEquity":0.4,"currentRatio":8.92,"returnOnAssets":-30.9,"returnOnEquity":-48.9,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":57.29,"targetHighPrice":90,"targetLowPrice":38,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":96.4,"sharesOutstanding":78492072,"floatShares":72361056,"sharesShort":7599353,"shortRatio":6.65,"shortPercentOfFloat":9.7,"epsTrailing":-4.27,"epsForward":-4.56,"revenuePerShare":0.01,"bookValue":6.85,"officers":[{"age":63,"name":"Mr. Anthony S. Marucci M.B.A.","title":"Founder, President, CEO & Director"},{"age":66,"name":"Dr. Tibor  Keler Ph.D.","title":"Founder, Chief Scientific Officer & Executive VP"},{"age":54,"name":"Mr. Sam  Martin CPA","title":"Senior VP, CFO, Secretary & Treasurer"},{"age":53,"name":"Ms. Elizabeth  Crowley","title":"Chief Product Development Officer & Senior VP"},{"age":68,"name":"Dr. Margo  Heath-Chiozzi M.D.","title":"Senior Vice President of Regulatory Affairs"},{"age":80,"name":"Prof. Joseph P. Schlessinger Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":50,"name":"Ms. Sarah  Cavanaugh","title":"Senior Vice President of Corporate Affairs & Administration"},{"age":56,"name":"Mr. Freddy A. Jimenez Esq.","title":"Senior VP & General Counsel"}],"industry":"Biotechnology","irWebsite":"http://www.avantimmune.com/","website":"https://www.celldex.com","phone":"908 200 7500"}}